CAS Insight

Drug Discovery IPOs in 2022Q1

We did a comprehensive review of industry news in 2022Q1 (there was.. a lot of stuff to cover). This article highlights companies focused on drug discovery that IPO’d in the first quarter.

The Drug Discovery IPO Market Slowdown

As everyone knows, biotech’s been in a bear market since Feb. 2021 (with the entire $XBI index down more than 50% since its peak). Record numbers of companies are valued below cash on hand, implying the average investor expects all of that cash to be spent with little return on investment.

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!